Huang Jane

About Huang Jane

Dr. Jane Huang is a biopharmaceutical medical executive known for her expertise in hematology, oncology, and global clinical development. Her most notable role at BeiGene, Ltd. was Chief Medical Officer, Hematology, a position she assumed after joining the company in September 2016. In that role, she led the medical and clinical strategy for BeiGene’s hematology portfolio, with oversight spanning key areas such as clinical pharmacology, global product safety, and late-stage development execution. Before joining BeiGene, Dr. Huang served as Vice President, Clinical Development at Acerta Pharma, where she oversaw the global clinical development of acalabrutinib, a BTK inhibitor that later became an important therapy in hematologic malignancies. That experience further established her as a senior leader in oncology drug development, with a focus on advancing innovative therapies through complex clinical programs. Prior to Acerta, she spent about a decade at Genentech, where she played a leading role in drug development programs across multiple molecules and stages of development. At BeiGene, she was part of the team responsible for advancing the company’s hematology strategy and clinical pipeline. Available sources indicate that she had strategic oversight of development for five hematology medicines and contributed to important regulatory and clinical milestones, including approvals of zanubrutinib in multiple diseases and the first approval of tislelizumab in Hodgkin’s lymphoma. Her career reflects a combination of scientific depth, operational leadership, and strong experience in moving oncology assets through global development pathways. Dr. Huang earned a Bachelor of Science degree in Biological Sciences from Stanford University and an M.D. from the University of Washington School of Medicine. She is board certified in hematology, oncology, and internal medicine, and completed her residency and fellowships at Stanford University. Overall, her profile is that of a senior medical leader who has helped guide the development of important cancer therapies across leading biotechnology companies.